Can You Have Fatty Liver With Normal Liver Enzymes?

Fatty liver disease is frequently present in people whose liver enzyme levels fall within the standard “normal” range. In one large prospective study, roughly a third of the entire cohort had fatty liver with normal enzymes, making this the single most common combination in the dataset. The mismatch between what liver blood tests show and what is actually happening inside the liver is one of the most clinically important blind spots in modern medicine, and it has real consequences for who gets diagnosed and who gets missed.

How Common Is Fatty Liver With Normal Enzymes

The numbers are striking. A large prospective study of more than 129,000 individuals found that 41,461 people, about 32% of the entire cohort, had fatty liver disease with normal liver enzyme levels. By comparison, only 16% had fatty liver with elevated enzymes.¹ That means roughly twice as many people with fatty liver had normal enzymes as had abnormal ones.

A study focused specifically on middle-aged adults who were overweight but had liver enzymes within the normal range found that over 40% of them already had fatty liver disease when researchers looked with imaging. Men were more affected than women, with about 47% of men and 36% of women meeting criteria for the condition.² Among people with high blood pressure and normal enzymes, the picture is similarly concerning: about 31% of hypertensive patients had fatty liver compared to roughly 13% of controls, despite everyone in the study having enzyme levels that would look unremarkable on a standard blood panel.³

Why Liver Enzymes Are a Poor Screening Tool for Fatty Liver

The enzyme most commonly checked is ALT (alanine aminotransferase). When liver cells are damaged or inflamed, ALT leaks into the bloodstream, and high levels signal that something is going wrong. But fatty liver, especially in its earlier stages, can involve fat accumulation without enough active cell death to push ALT above the lab’s cutoff. The liver is quietly storing excess triglycerides, driven by insulin resistance and increased fatty acid delivery, but the injury signal in the blood stays muted.⁴

ALT has historically been described as a marker of liver “injury,” but it was never designed to detect fat in the liver. As one review put it, ALT is not a test of liver function and does not necessarily predict worse outcomes in any given person. It is not a valid measure of the severity of liver injury or dysfunction. It picks up acute damage reasonably well but performs poorly as a screening tool for a chronic, slowly progressing condition like fatty liver disease.⁵

When researchers tested how reliably ALT identifies fatty liver using three of the most commonly used cutoff values, they found that ALT failed to rule out the disease in more than half of all cases.⁶ A test that misses over 50% of cases is, frankly, not a test anyone should rely on alone.

Normal Enzymes Do Not Mean Mild Disease

One of the more unsettling findings in this area is that people with fatty liver and normal ALT can have disease just as severe as those whose enzymes are elevated. A study comparing patients with normal and elevated ALT who were matched for body weight found that both groups had similar severity of the more aggressive form of the disease known as NASH (nonalcoholic steatohepatitis). The researchers concluded that enzyme levels are “misleading parameters for guiding clinical management.”⁷

The data on scarring is equally sobering. In a Vietnamese study using elastography to measure liver stiffness, over half of fatty liver patients with normal ALT levels already had significant fibrosis. There was no meaningful statistical difference in the rates of early and moderate fibrosis stages between the normal-ALT and elevated-ALT groups.⁸ A European study found that about a quarter of fatty liver patients with normal ALT had advanced fibrosis (stage 3 or 4), actually a higher rate than the 17% seen in patients whose ALT was elevated.⁹

That last finding deserves emphasis. Advanced fibrosis was more common in the normal-ALT group than in the elevated-ALT group. The intuition that “my enzymes are fine, so my liver must be fine” doesn’t just fail here; it inverts the actual risk.

The “Normal” Cutoff Problem

Part of the issue is that the standard upper limits for ALT used by most labs were set decades ago using reference populations that likely included people who already had undiagnosed fatty liver. The resulting cutoffs are almost certainly too generous. When researchers have recalculated healthier thresholds, the numbers come down substantially. One study of adolescents, for instance, found that an evidence-based upper limit of normal for ALT was about 30 IU/L for boys and 21 IU/L for girls, well below the 40 or even 55 IU/L cutoffs still printed on many lab reports.¹⁰

The gap between men and women matters too. When researchers in a pediatric population looked for the best ALT cutoffs to detect fatty liver, they landed at about 28 IU/L for girls and 27.5 IU/L for boys.¹¹ Using the conventional cutoff of 40 IU/L, a study in obese children found that sensitivity for detecting fatty liver dropped to just 61% in boys and a dismal 36% in girls. Lowering the cutoff to updated gender-specific thresholds boosted sensitivity to 84% in boys and 74% in girls.¹² In other words, the cutoffs your doctor’s lab uses can determine whether fatty liver is caught or invisible, and many of those cutoffs are outdated.

How Fatty Liver Gets Found When Enzymes Look Normal

If blood tests are unreliable, the question becomes: what does work? Imaging is the answer, and the options range in cost and accuracy.

Ultrasound is the most accessible first step and can detect moderate to severe fat accumulation, though it struggles with mild steatosis and is operator-dependent. For more precise measurement of liver fat, MRI-based proton density fat fraction (MRI-PDFF) is the gold standard in research settings. One head-to-head comparison found that MRI-PDFF identified moderate-or-greater steatosis with excellent accuracy, while the vibration-based measure called CAP (controlled attenuation parameter, available through FibroScan devices) performed well but measurably lower.¹³ Another multicenter study found that CAP with a cutoff of 280 dB/m had good accuracy for moderate to severe steatosis, making it a reasonable and more widely available alternative when MRI is impractical.¹⁴

For children, research has been direct: measurements of liver enzymes alone are insufficient, and liver ultrasonography is needed for early identification of fatty liver disease.¹⁵ The same principle applies to adults, but in practice most adults only get their liver investigated if their blood work comes back flagged, which, as the data above makes clear, misses the majority of cases.

Who Should Be Screened Even With Normal Enzymes

Updated European guidelines from the major liver, diabetes, and obesity societies now recommend that doctors look for fatty liver with fibrosis in people who have type 2 diabetes, or who have abdominal obesity plus at least one other metabolic risk factor, or who have abnormal liver tests. The point of listing abnormal liver tests as just one of three triggers is an acknowledgment that the first two categories, diabetes and metabolic obesity, are reasons to screen regardless of what the enzyme levels show.¹⁶

Metabolic syndrome is the strongest predictor of fatty liver in people whose enzymes look normal. In the middle-aged overweight cohort mentioned earlier, metabolic syndrome nearly tripled the odds of having the disease.² Even within populations whose enzymes are comfortably in range, liver enzyme levels track with the severity of metabolic syndrome features: higher BMI, worse insulin resistance, higher inflammatory markers.¹⁷ So a person can have “normal” ALT and still have values trending upward within that normal range in a way that correlates with worsening metabolic health. The label “normal” obscures a gradient.

Cardiovascular Risk Does Not Depend on Enzyme Levels

Fatty liver is increasingly understood as a condition whose most dangerous consequences are not always in the liver itself. Heart disease is the leading cause of death in people with fatty liver, and the association with cardiovascular disease persists regardless of whether liver enzymes are elevated. A large US population-based study found that fatty liver was independently associated with cardiovascular disease after adjusting for all major risk factors, and this held true in both the normal-enzyme and elevated-enzyme groups.¹⁸ If you have fatty liver, your cardiovascular risk is elevated whether your ALT is 18 or 80.

Treatment Response May Actually Differ

Here is something that complicates matters further. A 2025 study looked at how people with fatty liver and fibrosis responded to treatment depending on whether their ALT was normal or elevated. Both groups lost similar amounts of liver fat when treated. But people with elevated ALT and fibrosis were significantly more likely to see an improvement in their fibrosis stage compared to those who had fibrosis with normal ALT. In the elevated-ALT group, about 53% achieved at least a one-stage improvement in fibrosis, compared to roughly 32% in the normal-ALT group. The normal-ALT group also appeared to need more aggressive weight loss and fat reduction to achieve the same fibrosis improvement.¹⁹

This suggests that fatty liver with normal enzymes is not just the same disease caught earlier. It may have a somewhat different biology that is harder to reverse at the fibrosis level. The researchers found that the weight-loss threshold associated with fibrosis improvement was about 8.5% body weight in the normal-ALT group compared to about 5% in the elevated-ALT group. That is a meaningful practical difference for someone trying to treat the condition through lifestyle changes.

Weight Loss Still Works, But the Bar May Be Higher

Lifestyle intervention remains the frontline treatment for fatty liver regardless of enzyme status. Controlled studies have confirmed that losing roughly 7% to 10% of body weight can reduce liver fat, resolve the inflammatory form of the disease, and even improve fibrosis.²⁰ In overweight patients with chronic liver disease, those who achieved and maintained about 9% body weight loss saw sustained improvements in ALT, insulin levels, and quality of life over more than a year. Crucially, those who regained the weight saw their enzyme levels return to baseline.²¹

Even in obese patients whose ALT levels were already normal at the start, weight loss of about 9% brought ALT down further and improved insulin resistance, suggesting that “normal” enzymes in the setting of obesity are not truly healthy baseline values but already somewhat inflated.²² The implication is that even if your enzymes are technically in range, losing weight can move them into a genuinely healthier zone while simultaneously clearing fat from the liver.

Given the data from the 2025 study showing that fibrosis reversal in the normal-ALT group requires more weight loss, people in this category may need to aim for the higher end of the 7% to 10% range, or beyond, to see structural improvement in their liver. This is worth discussing with a doctor, especially because many people with normal enzymes never receive the fatty liver diagnosis that would motivate the lifestyle change in the first place.

Why the Enzyme-Centric Mindset Persists

Medical training and clinical workflows have long treated liver enzymes as a reliable first-line indicator of liver health. Insurance coverage for imaging often requires an abnormality on blood work to justify the test. Electronic health records flag abnormal results but do not flag the absence of a needed screen. The result is a system structurally biased toward catching fatty liver only in people whose enzymes happen to be elevated, which, as the data shows, is the minority of cases.

The shift toward recognizing metabolic risk factors as sufficient reason to screen, as the recent European guidelines recommend, is an important step. But implementation lags behind the guidelines. In most primary care settings around the world, a patient with a BMI of 32, prediabetes, and an ALT of 25 will be told their liver looks fine on blood work. The ALT of 25 is, statistically speaking, perfectly consistent with significant fatty liver disease and even early fibrosis. The patient walks away reassured, and the liver disease continues quietly progressing.

If you carry metabolic risk factors like central obesity, insulin resistance, type 2 diabetes, or metabolic syndrome, the lesson from this body of research is clear: normal liver enzymes are not a clean bill of liver health. They are a test designed for a different purpose, detecting acute injury, being asked a question they cannot reliably answer. Pursuing imaging-based assessment, particularly if you have multiple metabolic risk factors, is the more reliable path to knowing what is actually happening in your liver.